Key result
Minimally invasive AVR and ascending aorta replacement via right anterior thoracotomy shows 0% 30-day mortality.
Why the study?
Replacement of the aortic valve with concomitant replacement of the ascending aorta performed via a minimally invasive right anterior thoracotomy approach had not been reported.
Is minimally invasive aortic valve replacement with concomitant replacement of the ascending aorta via a right anterior thoracotomy approach feasible and safe?
Observational (n=20)
No
Is minimally invasive aortic valve replacement with concomitant replacement of the ascending aorta via a right anterior thoracotomy approach feasible and safe?
Minimally invasive aortic valve replacement with concomitant ascending aorta replacement via a right anterior thoracotomy approach is feasible and safe, demonstrating low morbidity and zero 30-day mortality in an initial cohort.
Answers are grounded in this paper and cite their sources.
Supports technical feasibility in selected patients; hypothesis-generating for minimally invasive combined aortic procedures pending prospective data.
OBJECTIVE: Replacement of the aortic valve with concomitant replacement of the ascending aorta performed via a minimally invasive right anterior thoracotomy approach has not been reported. We evaluated the feasibility and safety of this procedure. METHODS: We retrospectively reviewed all minimally invasive aortic valve replacements (AVRs) with concomitant replacement of the ascending aorta performed at our institution between January 1, 2012, and December 30, 2012. The operative times, intensive care unit and hospital lengths of stay, postoperative outcomes, as well as mortality were analyzed. RESULTS: A total of 20 consecutive patients who underwent minimally invasive AVR with concomitant replacement of the ascending aorta were identified. There were 16 men (80%), with a mean (SD) age of 61 (13) years. The mean (SD) left ventricular ejection fraction was 58% (8%). The aortic valve was bicuspid in 18 patients (80%), with 14 (70%) being stenotic. The median aortic cross-clamp and cardiopulmonary bypass times were 163 [interquartile range (IQR), 141-170] minutes and 291 (IQR, 177-215) minutes, respectively. Hypothermic circulatory arrest was required in 19 patients (95%), with a median hypothermic circulatory arrest time of 35 (IQR, 33-39.5) minutes. The median intensive care unit and hospital lengths of stay were 24 (IQR, 23-41) hours and 5 (IQR, 4-6) days, respectively. There were no strokes, reoperations for bleeding, or conversions to sternotomy. The 30-day mortality was zero. CONCLUSIONS: Minimally invasive AVR with concomitant replacement of the ascending aorta, via a right anterior thoracotomy approach, can be performed with low morbidity and mortality.
No takes yet. Share an insight, caveat, or question.
LaPietra et al. (2014) conducted an observational in Aortic valve disease requiring replacement with concomitant ascending aorta replacement (n=20). Minimally invasive aortic valve and concomitant ascending aorta replacement via right anterior thoracotomy was evaluated on 30-day mortality. Minimally invasive aortic valve and concomitant ascending aorta replacement via a right anterior thoracotomy approach was feasible and safe, with 0% 30-day mortality among 20 patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: